Paratek Pharmaceuticals, Inc.

222 articles with Paratek Pharmaceuticals, Inc.

• Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million

  3/16/2023

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2022.

• Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16

  3/8/2023

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, March 16, 2023 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full year 2022.

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - March 01, 2023

  3/1/2023

  Paratek Pharmaceuticals, Inc. announced that on February 28, 2023, the Company granted stock options and restricted stock units to four new employees of the Company.

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - February 01, 2023

  2/1/2023

  Paratek Pharmaceuticals, Inc. announced that on January 31, 2023, the Company granted stock options to four new employees of the Company.

• Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)

  1/18/2023

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China’s National Healthcare Security Administration (NHSA) has added the intravenous (IV) formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL).

• Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract

  1/5/2023

  Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced the receipt of a $36.4 million milestone payment associated with the second procurement of NUZYRA® (omadacycline) under the company’s Project BioShield contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.

• Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board

  12/20/2022

  Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company’s independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022.

• Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield

  12/19/2022

  Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s effectiveness in the treatment of pulmonary anthrax.

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - December 1, 2022

  12/1/2022

  Paratek Pharmaceuticals, Inc. today announced that on November 30, 2022, the Company granted restricted stock units to one new employee of the Company.

• Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

  11/21/2022

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces that Evan Loh, M.D., chief executive officer, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30 at 9:15 a.m. ET.

• Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million

  11/3/2022

  Paratek Pharmaceuticals, Inc., reported financial results and provided an update on corporate activities for the quarter ended September 30, 2022.

• Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference

  11/1/2022

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announces that Evan Loh, M.D., chief executive officer, will present at the Credit Suisse 31st Annual Healthcare Conference held Nov. 7-10.

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - November 01, 2022

  11/1/2022

  Paratek Pharmaceuticals, Inc. announced that on October 31, 2022, the Company granted stock options to four new employees of the Company.

• Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract

  10/31/2022

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces the commercial availability of U.S.-produced NUZYRA® (omadacycline) tablets.

• Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3

  10/25/2022

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30 p.m. ET to report its financial results for the third quarter of 2022.

• Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022

  10/13/2022

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces that new data from the NUZYRA® (omadacycline) non-clinical and investigator-initiated research programs will be presented at IDWeek 2022.

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - October 03, 2022

  10/3/2022

  Paratek Pharmaceuticals, Inc. announced that on September 30, 2022, the Company granted stock options and restricted stock units to twenty new employees of the Company.

• Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)

  9/26/2022

  Paratek Pharmaceuticals, Inc. today announces that the company will host an update for investors on the global opportunity for NUZYRA® (omadacycline) in non-tuberculous mycobacteria (NTM) on Monday, Oct. 3.

• Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/1/2022

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today announced that Paratek President and Chief Commercial Officer Adam Woodrow will participate in a virtual fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference.

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Sep 01, 2022

  9/1/2022

  Paratek Pharmaceuticals, Inc. announced that on August 31, 2022, the Company granted stock options to one new employee of the Company.